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Canceristhesecondleadingcauseofdeathintheworldaftercardiovasculardiseases.Sometypesofcancercellsoftentraveltoother
parts of the body through blood circulation or lymph vessels, where they begin to grow. This process is recognized as metastasis.
Angiogenesis is the formation of new blood vessels from existing vessel. Normally angiogenesis is a healthy process, that helps the
body to heal wounds and repair damaged body tissues, whereas in cancerous condition this process supports new blood vessels
formation that provide a tumor with its own blood supply, nutrients and allow it to grow. The most important proximal factor for
angiogenesis is the vascular endothelial growth factor VEGF. Angioinhibition is a form of targeted therapy that uses drugs to stop
tumors from making new blood vessels. Therefore, in this paper we analyse the importance of VEGF as target of cancer therapy,
analysing murine models.
1.Introduction
Angiogenesis, the process by which the existing vascular
network expands to form new blood vessels, is required
for the growth of solid tumors [1]. For this reason,
tumor angiogenesis has become a critical target for can-
cer therapy. Vascular endothelial growth factor (VEGF),
a primary stimulant of angiogenesis, binds and activates
VEGF receptor 1 (VEGFR1) and VEGFR2 [2]. VEGF is an
important and powerful factor increasing vascular perme-
ability and promoting metastasis. Without blood vessels,
the tumors can not be larger than a few millimeters, so
the inhibition of angiogenesis with the use of several drugs
could represent an important tool in cancer treatment
for several reasons. (1) Angiogenesis occurs at high levels
during fetal development, the menstrual cycle, and in
wound healing. Therefore, the treatments should have low
toxicity; in fact, they might be expected to interfere with
this process and should not harm most normal dividing
cells. (2) The antiangiogenic treatments should not be
designed to attack directly the cancer cells. The targets of
several of these treatments are normal processes controlled
by normal cells and not by the tumor cells themselves.
The high mutation rates of cancer cells that often render
chemotherapy ineﬀective will not interfere with these
drugs.
In this paper, we underline the importance of inhibition
of VEGF as attractive therapeutic target in the treatment of
cancer. VEGF is a primary stimulant for tumor angiogenesis,
making it a critical target for cancer therapy [3, 4]. In breast
cancer, elevated levels of VEGF correlate with increased
lymph node metastases and a worse prognosis [5]. Actually,
bevacizumab, a humanized monoclonal antibody that binds
human VEGF and prevents VEGF from binding VEGFR1
and VEGFR2, is approved for the treatment of metastatic
HER2/NEU-negative breast cancer [6].
2.VEGFandBreast Cancer
VEGF is a primary stimulant of angiogenesis and is a
macrophage chemotactic protein [7]. Inhibition of VEGF
is beneﬁcial in combination with chemotherapy for some
breast cancer patients. Anti-VEGF therapy with beva-
cizumab, the phenethylamine of the 2C family 2C3 or
the fully human antibody that inhibits VEGF binding to
VEGFR2 r84 inhibits the growth of established ortho-
topic MDA-MB-231 breast cancer cell line in severe com-
bined immunodeﬁciency (SCID) mice [8], reduces tumor2 Journal of Biomedicine and Biotechnology
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Figure 1: VEGF pathway and VEGF inhibitors.
microvessel density, and limits the inﬁltration of tumor-
associated macrophages, but it is associated with elevated
numbers of tumor-associated neutrophils [9, 10]. Selective
inhibition of VEGFR2 with an anti-VEGF antibody is suf-
ﬁcient for eﬀective blockade of the protumorigenic activity
of VEGF in breast cancer xenografts [6]. These ﬁndings
further deﬁne the complex molecular interactions in the
tumor microenvironment and provide a translational tool
that may be relevant to the treatment of breast cancer.
3. Inhibition of Tumor Breast Growth
Inhibition of VEGF binding to VEGFR2 by 2C3 has been
shown to reduce tumor size both in pancreatic [11–13]a n d
breast tumors [14]. Also the eﬀect on tumor growth after
the treatment with r84 in an orthotopic breast cancer model,
similar to 2C3, has been evaluated. In fact, MDA-MB-231
cells (5 × 106) were injected into the mammary fat pad
of nonobese diabetic NOD/SCID mice, and the therapy was
initiated on day 26 after tumoral cell injection, when tumor
volume reached 150 mm3. In this orthotopic human breast
cancerxenograftmodel,thechronictreatmentwithr84,2C3,
or bevacizumab signiﬁcantly reduced (P<. 001; days 44
and 48 versus control) the tumoral growth, such that there
was a 55%, 62%, and 58% decrease, respectively, in tumor
volume compared with control-treated animals. Thus, these
data show that inhibition of the VEGF factor is suﬃcient to
reduce the mass volume of MDA-MB-231-derived tumors.
To determine if the eﬀect of r84, 2C3, and bevacizumab on
MDA-MB-231 tumor growth in vivo could be due directly
to the block of VEGF activation of tumor cells, the tumor
cell proliferation and migration were also evaluated in vitro,
demonstrating that MDA-MB-231 cells migrated strongly
toward VEGF and, consequently, this migration was blocked
by the addition of 2C3, r84, or bevacizumab [8].
4. Effect of Anti-VEGF Therapy on
Tumor Environment
VEGF is an abundant cytokine in the tumor microenviron-
ment and is known to stimulate immune cell chemotaxis
[15];however,fewstudieshavelooked directlyattheeﬀectof
inhibitors of VEGF on immune cell inﬁltration into tumors.
It has been shown previously that 2C3 inhibits macrophage
inﬁltration in an orthotopic pancreatic cancer model [16,




MDA-MB-231 cells, anti-VEGF therapy with 2C3, r84, or
bevacizumab reduced tumor microvessel density by 50%,
45%, and 58%, respectively [8]. Cancer and inﬂammation
areconnectedbytwopathways:theintrinsicandtheextrinsic
pathways. These two pathways converge, resulting in the
activation of transcription factors, such as nuclear factor-
κB( N F - κB), signal transducer and activator of transcription
3 (STAT3), and hypoxia-inducible factor 1α (HIF1α), in
tumour cells. These transcription factors modulate the pro-
duction of inﬂammatory mediators, including cytokines and
chemokines [15]. These factors recruit and activate various
leukocytes. The cytokines activate the same key transcription
factors in inﬂammatory cells, stromal cells, and tumor cells,
resulting in more inﬂammatory mediators being produced
and a cancer-related inﬂammatory microenvironment being
generated. The mediators and cellular eﬀectors of inﬂam-
mation are important constituents of the local environmentJournal of Biomedicine and Biotechnology 3
of tumours; in some cancers, inﬂammatory conditions are
present before a malignant change occurs. To examine the
importance of inﬂammatory microenvironment on tumor
site, where a massive macrophage inﬁltration is associated,
breast tumors from bevacizumab, 2C3, or r84 treatment
groups were analyzed using three diﬀerent macrophage
markers: the mouse F4/80 antigen, a 160kD glycoprotein
expressed by murine macrophages, and CD16+ cells, a
clusterofdiﬀerentiationfoundonthesurfaceofnaturalkiller
cells, neutrophil polymorphonuclear leukocytes, monocytes,
and macrophages.
Immunoﬂuorescence staining of tumor sections revealed
that anti-VEGF therapy with 2C3, r84, and bevacizumab
reduced cluster of diﬀerentiation the inﬁltration of F4/80+
and of CD16+ natural killer cells, neutrophil polymor-
phonuclear leukocytes, monocytes and macrophages. The
reduction of macrophage inﬁltration in the phase of treat-
ment with 2C3 and r84 is presumably due to expression of
VEGFR2 on tumor-associated macrophages [8]. The major
ﬁndings of this study were that 2C3, r84, and bevacizumab
eﬀectively decrease tumor size, microvessel density, and
macrophage inﬁltration in an orthotopic model of breast
cancer. These data are consistent with previous ﬁndings
[16–18] and support the concept that reducing macrophage
inﬁltration is an important aspect of anti-VEGF therapy. In
addition, these studies showed changes in other immune
cell inﬁltrates: myeloid-derived suppressor cells (MDSCs),
dendritic cells (DCs), and neutrophils, following anti-VEGF
therapy. In fact, inﬁltrating inﬂammatory cells constitute a
large component of the overall tumor mass [19].
5. Anti-VEGFTherapy Leads to a Reduction
in Macrophage Inﬁltration
VEGF is a major chemoattractant for inﬂammatory cells
[15], including macrophages, neutrophils, dendritic cells,
myeloid-derived suppressor cells, and T-cells [20, 21].
To evaluate if inhibition of VEGF reduces angiogenesis
and modulates immune cell inﬁltration of orthotopic breast
cancer xenografts, Roland et al. [8] use preclinical models of
breast cancer to compare the eﬀect of diﬀerent anti-VEGF
therapies on breast cancer growth, vascular parameters,
immune cell inﬁltration, and intratumoral cytokine levels.
They conﬁrmed that the inhibition of VEGF receptor
activation resulted in changes in intratumoral levels of IL-
1 and CXCL1 that correlated with changes in immune cell
inﬁltration [8].
6.VEGFandLungCancer
VEGF represents a good candidate as target of therapy also
in lung cancer. In fact, Ma et al. constructed a plasmid
encoding VEGF shRNA to knock down VEGF both in
vitro and in vivo [22]. In vitro, speciﬁcity and potency of
the targeting sequence were ﬁrst validated in A549 lung
adenocarcinoma cells by RTPCR and ELISA assays. In vivo,
therapy experiments were conducted on nude mice bearing
A549 xenograft tumors. The VEGF shRNA expressing plas-
mids were administered systemically in combination with
low dose of cis-diclorodiamminoplatino (DDP) that is an
antineoplastic chemotherapy agent that interferes with all
phases of the cell cycle by binding to DNA through the for-
mation of crosslinks between complementary strands. The
combinated treatment of the two agents had a signiﬁcantly
enhanced antitumoral eﬀect compared with the treatment
with pshVEGF or DDP alone, resulting in reduction of
the tumor weight by 83.13% [22]. To demonstrate that
the therapeutic eﬀects were related to downregulation of
VEGF expression instead of other nonspeciﬁc reactions,
the tumors were harvested for immunohistochemistry and
ELISA assay to measure VEGF expression. It was analyzed
the distribution of immunoreactive VEGF in the tumors and
observed a general decrease of VEGF staining in the tumors
belonging to the mice treated with pshVEGF, whereas the
tumors belonging to the mice treated with pshHK exhibited
signiﬁcantly more VEGF staining. Consistently, the ELISA
assay showed that pshVEGF caused signiﬁcant reduction in
intratumoral VEGF expression compared with pshHK [22].
Thesedatareinforcethehypothesisthattheeﬀectofanti-
VEGF agents extends beyond the inhibition of angiogenesis
because many immune cells express VEGFRs, including
macrophages, neutrophils, MDSCs, DCs, and T-cells [23,
24]. In fact, it was shown a reduction in macrophage number
intumorsfromanimalstreatedwithanti-VEGFtherapywith
respect to the control mice [25].
7. Concluding Remarks
VEGF is a potent stimulator of endothelial cell survival,
mitogenesis, migration, and diﬀerentiation [1, 2]. Angio-
genesis inhibitors targeting VEGF have shown antitumoral
activity in preclinical and clinical trials. Several VEGF
inhibitors have been approved by the US Food and Drug
administration for the treatment of tumors or age-related
macular degeneration [3, 4]( Figure 1).
Recently,inmanyclinicaltrails,angioinhibitorswerealso
being used in combination with conventional chemotherapy.
Clinicaltrialsgenerallycombineverylowdoseofchemother-
apy followed by angioinhibitor therapy. Combination of
angioinhibitors will need to be tested vigorously in the
future, as single angioinhibitors are approved for use of
cancer.
Preventive angioinhibitory therapy may also be possible
in the future, because angioinhibitory therapy is generally
less toxic and less susceptible to induction of acquired drug
resistance.
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